URGN$29.9412.98%-4.465
Urogen Pharma Ltd (URGN)
Date: 2026-11-04 16:00O: 33.04H: 34.17L: 27.55C: 29.77Vol: 1.704M
Urogen Pharma Ltd stock is traded at $29.94, with a volume of 1,169,599. It is down -12.98% in the last 24 hours and down -27.69% over the past month. UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
Previous Close:
$34.40
Open:
$33.04
24h Volume:
1,169,599
Relative Volume:
1.03
Market Cap:
$1.46B
Revenue:
$140.49M
Net Income/Loss:
-$153.49M
P/E Ratio:
-
EPS:
-$2.76
Net Cash Flow:
-$175.90M
1W Performance:
-11.30%
1M Performance:
-27.69%
6M Performance:
+28.53%
1Y Performance:
+51.11%
1-Day Range:
$27.55$34.17
1-Week Range:
$32.39$34.97
52-Week Range:
$16.50$50.81
Urogen Pharma Ltd Stock (URGN) Company Profile
Name
Urogen Pharma LtdSector
HealthcareIndustry
BiotechnologyPhone
972 9 770 7601Address
9 HA'TA'ASIYA ST, RA'ANANA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
Urogen Pharma Ltd Stock (URGN) Financials Data
Urogen Pharma Ltd Stock (URGN) Insider Trading
- Christopher DegnanOct 08 '26Officer
- Transaction
- Proposed Sale
- Cost
- $40.70
- #Shares
- 2,202
- Value ($)
- 89,621
- #Shares Total
- 0
- Degnan ChrisOct 08 '26Chief Financial Officer
- Transaction
- Sale
- Cost
- $36.69
- #Shares
- 2,202
- Value ($)
- 80,791
- #Shares Total
- 4,561
- Smith Jason DrewSep 08 '26General Counsel
- Transaction
- Sale
- Cost
- $42.54
- #Shares
- 1,519
- Value ($)
- 64,618
- #Shares Total
- 53,141
- Schoenberg MarkSep 08 '26Chief Medical Officer
- Transaction
- Sale
- Cost
- $42.92
- #Shares
- 871
- Value ($)
- 37,383
- #Shares Total
- 59,882
- Jason SmithSep 08 '26Officer
- Transaction
- Proposed Sale
- Cost
- $44.09
- #Shares
- 1,519
- Value ($)
- 66,973
- #Shares Total
- 0
- Mark SchoenbergSep 08 '26Officer
- Transaction
- Proposed Sale
- Cost
- $44.09
- #Shares
- 871
- Value ($)
- 38,402
- #Shares Total
- 0
- Schoenberg MarkAug 20 '26Chief Medical Officer
- Transaction
- Sale
- Cost
- $47.05
- #Shares
- 60,677
- Value ($)
- 2,854,853
- #Shares Total
- 59,086
- Schoenberg MarkAug 20 '26Officer
- Transaction
- Proposed Sale
- Cost
- $47.67
- #Shares
- 60,677
- Value ($)
- 2,892,242
- #Shares Total
- 0
- Schoenberg MarkJul 09 '26Officer
- Transaction
- Proposed Sale
- Cost
- $40.00
- #Shares
- 10,000
- Value ($)
- 400,008
- #Shares Total
- 0
- Schoenberg MarkJul 09 '26Chief Medical Officer
- Transaction
- Sale
- Cost
- $40.00
- #Shares
- 10,000
- Value ($)
- 400,000
- #Shares Total
- 119,763
